Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 18, 2006

$52M Awarded for Alzheimer’s Research

  • The Alzheimer’s Disease Cooperative Study, a federally established consortium conducting clinical trials on Alzheimer’s Disease (AD), will receive $52 million over six years to conduct several new trials.

    The award will help test drugs for their effectiveness in slowing down the progression or treating the symptoms of AD, as well as to investigate new methods for conducting dementia research. Specifically, researchers will focus on possible therapies aimed at affecting the beta amyloid peptide and the tau protein, both of which are involved in the development of AD.

    The award is a cooperative agreement between the National Institute on Aging’s (NIA) and the University of California, San Diego (UCSD), which coordinates the consortium of nearly 70 sites in the U.S. and Canada.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »